A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma
about
Mepolizumab versus placebo for asthmaThe Efficacy and Safety of Antiinterleukin 13, a Monoclonal Antibody, in Adult Patients With Asthma: A Systematic Review and Meta-AnalysisTh17-mediated inflammation in asthmaBiomolecular markers in assessment and treatment of asthmaTargeting interleukin-4 in asthma: lost in translation?Refractory asthma: mechanisms, targets, and therapy.Cytokine/anti-cytokine therapy - novel treatments for asthma?IL-13 regulates Th17 secretion of IL-17A in an IL-10-dependent manner.Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targetsRole of IL-6 in asthma and other inflammatory pulmonary diseases.A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthmaSafety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study.Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patientsIL-17A induces signal transducers and activators of transcription-6-independent airway mucous cell metaplasia.Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.Asthma: developments in targeted therapy.Disabling inflammatory pathways with biologics and resulting clinical outcomes in severe asthma.Asthma: beyond corticosteroid treatment.Asthma: the importance of dysregulated barrier immunity.CLCA1 and TMEM16A: the link towards a potential cure for airway diseases.A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis.Novel monoclonal treatments in severe asthma.Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal Antibody.Rapid development of multiple 'fit-for-purpose' assays on an automatic microfluidic system using a streamlined process in support of early biotherapeutics discovery programs.Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor.Dose-Exposure-Response Relationship of the Investigational Anti-Interleukin-13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma.Copper oxide nanoparticles aggravate airway inflammation and mucus production in asthmatic mice via MAPK signaling.Nebulized anti-IL-13 monoclonal antibody Fab' fragment reduces allergen-induced asthma.Anti-IL5 therapies for asthma.Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review.Homoegonol attenuates the asthmatic responses induced by ovalbumin challengePathology of asthma
P2860
Q24186306-03BA4202-BC52-41A3-ADA1-99BFEDA2CE1EQ26766300-EDC7CEF7-72AE-4657-94D4-08A6EF57EF13Q26861492-D3850498-5B91-4402-91BD-B50C1F6DB365Q26994979-0061E983-B52F-4705-96E7-4E12453792BDQ34271232-8A57F31A-45C8-4AF9-8DD3-5F3AB71CDAB2Q34788832-5F9B4012-0467-4EC6-A7F5-9D1F0C2A8310Q34903133-936E538A-A64A-4462-BA6E-81600EF5E6FBQ35685575-A67F98D7-A3EA-43C0-9921-8509A5AE6C67Q35952040-743DA697-D2F6-4A53-8F9E-FD2EC82FDF5BQ36378245-334D087A-8327-4970-B3E8-E404223919A4Q36579400-126A9B2B-5B8D-43B3-B32E-A5FEFC3AE3D9Q36792978-420F1017-CFE7-4A7A-8D0D-3A9F4D964214Q36806646-CE880477-E1B4-4985-95A4-3F6516AD233FQ37056449-42CC9015-D473-4200-9AF8-32FC844EF45BQ37298794-33A61FC8-7B14-4F5D-9E3E-069E3BCE26E4Q37965598-57C9F438-A90E-4742-A9E7-1B2318DD8140Q38071691-CBCAC07D-0691-44AD-A1C6-FE5BEC1623CAQ38121086-1770955C-FDB4-4238-8356-C3803455E1AFQ38156031-474BDD0A-8F80-4A8D-9420-EF7D5E5AED97Q38571104-151C91B2-6196-4A77-8204-D267EA10313CQ38634828-8972F64E-5952-4764-9CD4-CF4402903B56Q38911706-0C201C3F-7830-4273-B78A-6810CABC9F9BQ41433501-A0C102C5-72FF-4772-B26C-01ACB55CE41FQ44287563-C74B5C3C-7FCA-4612-857C-2D75EC439F8CQ44699279-A7983F8A-6A64-4063-ADEC-09C01011AA51Q46421874-63B3041B-F4DB-4412-99B6-0FD7D76F6951Q46653423-E4AE326B-C107-473D-9E58-A56F75B66FD0Q47246192-13FC2F6E-0ED7-4833-8345-DE10653EEA82Q47551081-E99C0BFD-6F30-49EF-BB7E-CC2AD3A5936BQ50108035-A8193B1D-7E55-409F-8726-AECA158E3AECQ57223390-AE157331-2679-4526-851B-92CFAA6EC154Q57901630-948ED80B-9524-4294-AAC6-3BDFB129C694
P2860
A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A phase 1 study evaluating the ...... T-354) in subjects with asthma
@ast
A phase 1 study evaluating the ...... T-354) in subjects with asthma
@en
A phase 1 study evaluating the ...... -354) in subjects with asthma.
@nl
type
label
A phase 1 study evaluating the ...... T-354) in subjects with asthma
@ast
A phase 1 study evaluating the ...... T-354) in subjects with asthma
@en
A phase 1 study evaluating the ...... -354) in subjects with asthma.
@nl
prefLabel
A phase 1 study evaluating the ...... T-354) in subjects with asthma
@ast
A phase 1 study evaluating the ...... T-354) in subjects with asthma
@en
A phase 1 study evaluating the ...... -354) in subjects with asthma.
@nl
P2093
P2860
P356
P1476
A phase 1 study evaluating the ...... T-354) in subjects with asthma
@en
P2093
Binita Kane
Dave Singh
Lorin Roskos
Nestor A Molfino
Raffaella Faggioni
P2860
P2888
P356
10.1186/1471-2466-10-3
P577
2010-01-08T00:00:00Z
P5875
P6179
1011889763